Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC022F CAR-T for Relapsed/Refractory B-ALL
NCT04129099Phase 1Unknown
- Sponsor
- Lu Daopei Hospital
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of GC022 in acute lymphoblastic leukemia (ALL), sponsored by Lu Daopei Hospital. Primary endpoint: Adverse Events at 2 years. Status: unknown.
02
Drugs
GC022
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04129099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129099.